American Regent, a US-based company that has been developing, manufacturing, and supplying generic and branded injectables, announced on Tuesday that is has introduced its 30 mL Epinephrine Injection, USP in United States.

The injection is intended for emergency treatment of allergic reactions (Type I), which includes anaphylaxis that can result from insect stings or bites, foods, drugs, sera, diagnostic testing substances and other allergens, and idiopathic anaphylaxis or exercise-induced anaphylaxis. It is also intended to raise mean arterial blood pressure in adult patients with hypotension related with septic shock. It is available as a 30 mg/30 mL (1 mg/mL) multiple-dose vial in a shelf pack of one.

Epinephrine Injection is available for immediate shipment. Orders for the product can be placed through a customer's wholesaler/distributor, or by contacting American Regent's Customer Support Group.

Joann Gioia, vice president and chief commercial officer at American Regent, Inc, said: "With the approval of Epinephrine Injection, USP we continue to show our commitment to ensuring both patients and providers have access to high-quality treatment options."